Iradimed (IRMD) Receivables (2013 - 2026)

Iradimed (IRMD) has reported Receivables for 14 consecutive years, with $13.2 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Receivables rose 20.78% year-over-year to $13.2 million in Q2 2026; TTM through Jun 2026 was $13.2 million, a 20.78% increase from a year earlier, with the FY2025 full-year figure at $13.7 million, up 29.47% from the prior year.
• Receivables was $13.2 million for Q2 2026 at Iradimed, down from $13.4 million in the prior quarter.
• Over five years, Receivables peaked at $13.9 million in Q3 2025 and troughed at $6.5 million in Q1 2022.
• A 5-year average of $11.7 million and a median of $12.1 million in 2023 frame the typical range for Receivables.
• Across the five-year window, Receivables surged 158.43% in 2022 and decreased 18.92% in 2024, its largest moves.
• Over 5 years, Receivables stood at $13.3 million in 2022, then retreated by 7.91% to $12.2 million in 2023, then dropped by 13.65% to $10.6 million in 2024, then gained by 29.47% to $13.7 million in 2025, then fell by 3.48% to $13.2 million in 2026.
• The last three Receivables figures came in at $13.2 million (Q2 2026), $13.4 million (Q1 2026), and $13.7 million (Q4 2025), per Business Quant data.